Plain English Summary
Background and study aims
Parkinson's disease is a condition in which parts of the brain become progressively damaged over many years. The main symptoms are related to movement, but there are also a variety of mental symptoms. Executive functions are mental skills that help the brain organize and act on information. Problems with executive functions (impairments) are frequently found in Parkinson's disease patients and can already be present in the early stages of the disease. This can lead to reduced independence in daily life and to a lower quality of life. It is already common in other patient groups to offer cognitive rehabilitation programs for these impairments. Cognitive rehabilitation is a behavioural treatment which focuses on improving everyday functioning through management of cognitive (thinking) difficulties. However, this is not yet part of standard treatment for Parkinson's disease patients. Therefore, the aim of this study is to find out whether strategic executive training (ReSET, teaching general planning strategies) is better at improving daily life executive functioning and quality of life than computerized function training (Cogniplus, repeated practice of attention tasks).
Who can participate?
Patients aged 18-80 with Parkinson's disease
What does the study involve?
Participants are randomly allocated to one of two groups. Participants in one group receive the ReSET treatment. ReSET contains three modules: information and awareness; goal setting and planning; and initiative and regulation, in which participants are taught several strategies that can be applied to a broad range of daily life situations. Participants in the other group receive the Cogniplus treatment. Cogniplus aims at training several aspects of attention (e.g. selective, sustained attention) by repeated practice of several tasks. Both treatments are individually administered and consist of 14 one-hour sessions. Before treatment, at maximum 2 weeks after treatment and at 3-5 months follow-up participants’ executive functions are assessed with tests and questionnaires.
What are the possible benefits and risks of participating?
Possible benefits are improvements of executive impairments in daily life functioning and maybe even an improvement of quality of life. There are no risks involved when participating in this study.
Where is the study run from?
1. University Medical Centre Groningen (Netherlands) (lead centre)
2. Maastricht University Medical Centre (Netherlands)
3. Nij Smellinghe, a medical centre in Drachten (Netherlands)
When is the study starting and how long is it expected to run for?
September 2010 to November 2014
Who is funding the study?
The Dutch Organization for Scientific Research (NWO), the National Initiative Brain and Cognition (NIHC) (Netherlands)
Who is the main contact?
1. T. Vlagsma (public)
2. Prof. Dr J.M. Spikman (scientific)
Trial website
Contact information
Type
Scientific
Primary contact
Mrs Thialda Teakje Vlagsma
ORCID ID
Contact details
University Medical Center Groningen
Department Neuropsychology (AB60)
Hanzeplein 1
Groningen
9700 RB
Netherlands
Type
Scientific
Additional contact
Prof Jacoba M Spikman
ORCID ID
Contact details
University Medical Center Groningen
Department Neuropsychology (AB60)
Hanzeplein 1
Groningen
9700 RB
Netherlands
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
NL34792.042.11
Study information
Scientific title
The efficacy of ReSET, a Strategic Executive Treatment for executive dysfunction in patients with Parkinson’s disease
Acronym
ReSET
Study hypothesis
ReSET, a Strategic Executive Treatment, is more effective at improving Parkinson’s disease (PD) patients' executive dysfunctions in daily life functioning and their related participation in societal domains and quality of life than a computerized training for aspects of attention (Cogniplus).
Ethics approval
Medical ethics committee of the University Medical Center Groningen, 14/04/2011, ref: NL34792.042.11
Study design
Multicentre randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet.
Condition
Parkinson's disease
Intervention
Patients are blindly allocated to the following two groups by drawing lots. In order to balance the allocation of patients to both treatment conditions, lots are drawn per 4 patients (i.e. 2 experimental and 2 control lots). A co-worker who is not actively involved in the study is responsible for drawing lots.
1. Experimental treatment - ReSET: strategic executive training for dysfunctions in executive functions. ReSET contains three modules: information and awareness; goal setting and planning; and initiative and regulation. Patients are taught several strategies that can be applied to a broad range of daily life situations.
2. Control treatment - Cogniplus: computerized cognitive training for aspects of attention. Cogniplus aims at training several aspects of attention (e.g. selective, sustained attention) by repeated practice of several tasks.
Both treatment programs are individually administered to patients and consist of 14 one-hour sessions. Before, at maximum 2 weeks post-treatment and at 3-5 months follow-up an extensive neuropsychological assessment focused on executive functions (including tests and questionnaires) is administered.
Intervention type
Behavioural
Phase
Drug names
Primary outcome measures
Patients’ level of participation in different societal domains (i.e. work, social relations, leisure activities and mobility), measured using the Role Resumption list (RRL) at baseline, two weeks post-treatment and at 3-5 months follow-up
Secondary outcome measures
Measured at baseline, 2 weeks post-treatment and at 3-5 months follow-up:
1. Attainment of three individual executive goals set by patients during the third session of ReSET or Cogniplus, measured using the Treatment Goal Attainment scale
2. Problems in executive functioning in daily life, measured using the Dysexecutive Questionnaire, completed by participants and someone who had a good insight into the patients’ functioning in daily life
3. Quality of life, measured using the Parkinson's Disease Questionnaire (PDQ-39)
4. Behavioural functioning, measured using executive subscales of the Brock Adaptive Functioning Questionnaire (BAFQ) (participant and significant other ratings)
5. Caregiver burden, measured using the Zarit Burden Interview
6. Executive functions (planning skills, inhibition, abstract reasoning, problem solving and estimation of time), measured using the Behavioural Assessment of the Dysexecutive Syndrome (BADS)
7. Selective attention and attentional switching or cognitive flexibility, measured using the Test of Everyday Attention (TEA)
Overall trial start date
01/09/2010
Overall trial end date
01/11/2014
Reason abandoned
Eligibility
Participant inclusion criteria
1. Patients diagnosed with idiopathic Parkinson's disease according to the UK Parkinson’s Disease Brain Bank Criteria, with disease severity ≤ Hoehn & Yahr (H&Y) stage 3
2. Age range 18-80 years
3. Patients had to be motivated for treatment
4. Patients had to report problems with EF in daily life that were experienced as burdensome (based on semi-structured interview and/or a total score of ≥18 on the Dysexecutive Questionnaire (DEX) and/or showed impairments on objective neuropsychological tests of executive function (EF):
4.1. A standard score of ≤2 on the subtests Zoo Map Test or Six Elements Test of the Behavioural Assessment of the Dysexecutive Syndrome (BADS) and/or
4.2. A standard age total score on the BADS categorized as “low average” or lower and/or
4.3. A discrepancy of 15 points between standard age score and premorbid IQ as measured with the short version of the Dutch Groninger Intelligence Test
5. Patients had to speak and understand the Dutch language
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
90
Participant exclusion criteria
1. Severe neurological comorbidity, such as traumatic brain injury or stroke
2. Severe psychiatric symptoms, such as hallucinations, delusions or depression
3. Severe cognitive comorbidity: e.g. amnestic syndrome, global aphasia, neglect, severe memory problems, PD dementia (i.e. SCales for Outcomes in PArkinson’s disease-COGnition scale score ≤17)
4. Hoehn & Yahr stage 4 and 5
Recruitment start date
03/08/2011
Recruitment end date
16/07/2014
Locations
Countries of recruitment
Netherlands
Trial participating centre
University Medical Center Groningen (UMCG)
Groningen
9700RB
Netherlands
Trial participating centre
Maastricht University Medical Center (MUMC)
Maastricht
6229 HX
Netherlands
Trial participating centre
Medical center Nij Smellinghe
Drachten
9202 NN
Netherlands
Sponsor information
Organisation
Dutch Organization for Scientific Research (NWO), the National Initiative Brain and Cognition (NIHC)
Sponsor details
National Initiative Brain and Cognition
Laan van Nieuw Oost-Indië 300
The Hague
2593 CE
Netherlands
Sponsor type
Research organisation
Website
http://www.nwo.nl/en/about-nwo/organisation/nwo-divisions/nihc
Funders
Funder type
Research organisation
Funder name
Dutch Organization for Scientific Research (NWO), the National Initiative Brain and Cognition (NIHC)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
The results of the study are expected to be published in February/March 2017.
IPD sharing plan
The current data sharing plans for the current study are unknown and will be made available at a later date
Intention to publish date
01/03/2017
Participant level data
To be made available at a later date
Results - basic reporting
Publication summary